Optimizing the Dosing Regimens of Tigecycline against Vancomycin-Resistant Enterococci in the Treatment of Intra-abdominal and Skin and Soft Tissue Infections
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Tigecycline was previously considered to have activity against vancomycin-resistant Enterococcus (VRE) isolates, but the optimal dose was not clarified. Thus, this study assessed the in vitro activity of tigecycline against clinical VRE isolates to determine its optimal regimens for complicated intra-abdominal (cIAIs) and complicated skin/soft tissue infections (cSSTIs). We used Monte Carlo simulation to calculate the probability of target attainment (PTA) and the cumulative fraction of response for the ratio of the free area under the curve to the minimum inhibitory concentration (MIC) (fAUIC24), which were 17.9 and 6.9 for treating cSSTIs and cIAIs, respectively. All clinical isolates were Enterococcus faecium. Only a maintenance dose of 200 mg/day tigecycline gave the target attainment of fAUIC24 >17.9, and PTA exceeded 90% for MIC ≤0.38 µg/mL. Meanwhile, this dose gave the target attainment of fAUIC24 >6.9, and PTA exceeded 90% for MIC ≤1 µg/mL. All simulated tigecycline dosing regimens met the fAUIC24 targets more than 90% of the cumulative fraction of response. Despite its apparent efficacy, a daily tigecycline dose of 200 mg is recommended for VRE isolates with MICs of ≤0.38 µg/mL and ≤1 µg/mL for treating cSSTIs and cIAIs, respectively.
Abstract
Tigecycline was previously considered to have activity against vancomycin-resistant Enterococcus (VRE) isolates, but the optimal dose was not clarified. Thus, this study assessed the in vitro activity of tigecycline against clinical VRE isolates to determine its optimal regimens for complicated intra-abdominal (cIAIs) and complicated skin/soft tissue infections (cSSTIs). We used Monte Carlo simulation to calculate the probability of target attainment (PTA) and the cumulative fraction of response for the ratio of the free area under the curve to the minimum inhibitory concentration (MIC) (fAUIC24), which were 17.9 and 6.9 for treating cSSTIs and cIAIs, respectively. All clinical isolates were Enterococcus faecium. Only a maintenance dose of 200 mg/day tigecycline gave the target attainment of fAUIC24 >17.9, and PTA exceeded 90% for MIC ≤0.38 µg/mL. Meanwhile, this dose gave the target attainment of fAUIC24 >6.9, and PTA exceeded 90% for MIC ≤1 µg/mL. All simulated tigecycline dosing regimens met the fAUIC24 targets more than 90% of the cumulative fraction of response. Despite its apparent efficacy, a daily tigecycline dose of 200 mg is recommended for VRE isolates with MICs of ≤0.38 µg/mL and ≤1 µg/mL for treating cSSTIs and cIAIs, respectively.
참고문헌 (23)
- O'Driscoll T, "Vancomycin-resistant enterococcal infections : epidemiology, clinical manifestations, and optimal management", Infect Drug Resist, 8, pp.217~230 (2015)
- Sievert DM, "Antimicrobial-resistant pathogens associated with healthcare-associated infections : summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010", Infect Control Hosp Epidemiol, 34, pp.1~14 (2013)
- Annual surveillance reports on antimicrobial resistance, "European Centre for Disease Prevention and Control (ECDC)", ~ (2018)
- "Antibiogram 2018"[URL]
- Hemapanpairoa J, "Vancomycin-resistant enterococcal infection in a Thai university hospital : clinical characteristics, treatment outcomes, and synergistic effect", Infect Drug Resist, 12, pp.2049~2057 (2019)
- Suleyman G, "Safety and efficacy of commonly used antimicrobial agents in the treatment of enterococcal infections : a review", Expert Opin Drug Saf, 15, pp.153~167 (2016)
- Kresken M, "Temporal trends of the in vitro activity of tigecycline and comparator antibiotics against clinical aerobic bacterial isolates collected in Germany, 2006-2014: results of the Tigecycline Evaluation and Surveillance Trial (TEST)", GMS Infect Dis, 4, pp.Doc07~ (2016)
- Mercuro NJ, "Combatting resistant enterococcal infections : a pharmacotherapy review", Expert Opin Pharmacother, 19, pp.979~992 (2018)
- Sotgiu G, "Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB : systematic review and meta-analysis", Eur Respir J, 40, pp.1430~1442 (2012)
- "Identifying healthcare-associated infections (HAI) for NHSN surveillance"[URL]
- Clinical and Laboratory Standards Institute (CLSI), "Performance standards for antimicrobial susceptibility testing. M100. 29th ed", CLSI, 149~ (2019)
- Borsuk-De Moor A, "Population pharmacokinetics of high-dose tigecycline in patients with sepsis or septic shock", Antimicrob Agents Chemother, 62, pp.e02273~e02317 (2018)
- Meagher AK, "Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections", Antimicrob Agents Chemother, 51, pp.1939~1945 (2007)
- Passarell JA, "Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections", Antimicrob Agents Chemother, 52, pp.204~210 (2008)
- Asín-Prieto E, "Applications of the pharmacokinetic", pharmacodynamic(PK, J Infect Chemother, pp.2015, 21[DOI]
- Zhang Z, "Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial", Antimicrob Resist Infect Control, 7, pp.152~ (2018)
- Sader HS, "Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide(2011)", Diagn Microbiol Infect Dis, 76, pp.217~221 (2013)
- Chen YH, "Trends in the susceptibility of clinically important resistant bacteria to tigecycline : results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010", Antimicrob Agents Chemother, 56, pp.1452~1457 (2012)
- Santimaleeworagun W, "Optimizing the dosing regimens of daptomycin based on the susceptible dose-dependent breakpoint against vancomycin-resistant enterococci infection", Antibiotics(Basel), 8, pp.245~ (2019)
- Pankey GA, "In vitro antibacterial activity of tigecycline against resistant Gram-negative bacilli and enterococci by time-kill assay", Diagn Microbiol Infect Dis, 64, pp.300~304 (2009)
- Landman D, "Management of infections due to resistant enterococci : a review of therapeutic options", J Antimicrob Chemother, 40, pp.161~170 (1997)
- Xie J, "Population pharmacokinetics of tigecycline in critically ill patients with severe infections", Antimicrob Agents Chemother, 61, pp.e00345~e00417 (2017)
- McGovern PC, "All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials", Int J Antimicrob Agents, 41, pp.463~467 (2013)